DexCom, Inc. (DXCM)
| Market Cap | 33.82B +4.8% |
| Revenue (ttm) | 4.97B +15.5% |
| Net Income | 999.70M +74.9% |
| EPS | 2.54 +77.4% |
| Shares Out | 377.36M |
| PE Ratio | 35.15 |
| Forward PE | 31.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,448,502 |
| Open | 88.17 |
| Previous Close | 89.16 |
| Day's Range | 87.51 - 89.71 |
| 52-Week Range | 54.11 - 92.59 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 94.12 (+5.02%) |
| Earnings Date | Jul 30, 2026 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $94.12, which is an increase of 5.02% from the latest price.
News
The Big 3: PH, DXCM, UNP
Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportuni...
DexCom price target raised to $105 from $88 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on DexCom (DXCM) to $105 from $88 and keeps a Buy rating on the shares. The firm is more optimistic on…
DexCom price target raised to $96 from $86 at Argus
Argus analyst Steve Silver raised the firm’s price target on DexCom (DXCM) to $96 from $86 and keeps a Buy rating on the shares. DexCom’s strong Q2 execution and positive…
DexCom price target raised to $90 from $82 at Canaccord
Canaccord raised the firm’s price target on DexCom (DXCM) to $90 from $82 and keeps a Buy rating on the shares. The firm said guidance was raised for the second…
DexCom price target raised to $92 from $86 at Deutsche Bank
Deutsche Bank analyst Kieran Ryan raised the firm’s price target on DexCom (DXCM) to $92 from $86 and keeps a Buy rating on the shares.
DexCom price target raised to $94 from $91 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on DexCom (DXCM) to $94 from $91 and keeps a Strong Buy rating on the shares. DexCom’s Q2 results highlighted…
DexCom price target raised to $90 from $80 at BTIG
BTIG raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares. The company’s Q2 EPS was better than consensus, helped…
DexCom price target raised to $82 from $77 at Benchmark
Benchmark raised the firm’s price target on DexCom (DXCM) to $82 from $77 and keeps a Buy rating on the shares.
DexCom price target raised to $95 from $88 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $95 from $88 and keeps an Overweight rating on the shares. The firm notes the company…
DexCom price target raised to $95 from $90 at Mizuho
Mizuho raised the firm’s price target on DexCom (DXCM) to $95 from $90 and keeps an Outperform rating on the shares.
DexCom price target raised to $82 from $65 at JPMorgan
JPMorgan raised the firm’s price target on DexCom (DXCM) to $82 from $65 and keeps a Neutral rating on the shares. The firm says the company’s quarterly beat will support…
DexCom price target raised to $105 from $80 at Baird
Baird raised the firm’s price target on DexCom (DXCM) to $105 from $80 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which…
DexCom price target raised to $95 from $90 at Stifel
Stifel raised the firm’s price target on DexCom (DXCM) to $95 from $90 and keeps a Buy rating on the shares.
DexCom price target raised to $88 from $84 at Citi
Citi raised the firm’s price target on DexCom (DXCM) to $88 from $84 and keeps a Buy rating on the shares. The company reported better than expected results and has…
Dexcom raises annual revenue forecast on strong demand for glucose monitors
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar lev...
DexCom Earnings Call Transcript: Q2 2026
Q2 2026 delivered 13% revenue growth, record new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance was raised for revenue and margins, with continued growth expected as G7 15-day adoption accelerates.
DexCom Slides: Q2 2026
DexCom has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
DexCom Earnings release: Q2 2026
DexCom released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
DexCom Quarterly report: Q2 2026
DexCom has published its Q2 2026 quarterly earnings report on July 30, 2026.
DexCom reports Q2 EPS 70c, consensus 61c
Reports Q2 revenue $1.31B, consensus $1.29B. “During the quarter, we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity…
DexCom sees FY25 revenue $5.15B-$5.25B, consensus $5.22B
Guides FY26: Non-GAAP Gross Profit Margin of approximately 64%; Non-GAAP Operating Margin of approximately 23.5-24%; Adjusted EBITDA Margin of approximately 31.5-32%.
Dexcom Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participa...
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Gluc...